DESTINY-Breast03 Phase 3 Study Results

PATIENT-REPORTED OUTCOMES FROM DESTINY-Breast03, A RANDOMIZED PHASE 3 STUDY OF TRASTUZUMAB DERUXTECAN (T- DXD) VS TRASTUZUMAB EMTANSINE (T-DM1) IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER GIUSEPPE CURIGLIANO, KYLE DUNTON, MATS ROSENLUND, MARTIN JANEK, JILLIAN CATHCART, YALI LIU, PETER A. FASCHING, HIROJI IWATA Giuseppe Curigliano, MD European Institute of Oncology IRCCS, University of Milan, Milan, Italy Daiichi-Sankyo ESMO BC 2022 #1630 Oral On behalf of the investigators 36

View entire presentation